Quantified Imaging, originating from the University of Nottingham, specialises in advanced MRI techniques to improve dementia care, diagnosis, monitoring, and treatment.
Study suggests that long COVID patients are more likely to face blood-clots - even if they appeared okay, their clotting biomarkers were significantly high.
Dr Rutger Zietsma – CEO at Manus Neurodynamica Ltd – and PD Dr Angela Deutschländer share their vision on earlier diagnosis and objective symptom tracking with the NeuroMotor PenTM.
Richie Kohman, Synthetic Biology Platform Lead, Wyss Institute at Harvard, tells us all about Next Generation Sequencing in analysing synthetic biology signatures in brain tissue.
Researchers believe that they have found a PTSD marker in the brain region associated with emotional regulation - with the marker being strongest in people with "impaired executive dysfunction".
Indiana University of Medicine researchers spent four years developing a blood test to identify depression and bipolar disorder - they say this work will bring psychiatry from "the 19th century into the 21st".
Researchers at Yale believe that blood tests could predict severe or critical COVID cases, because blood holds a series of interesting biological signals about a person.
Salk Institute scientists believe they have solved this mystery for bipolar disorder patients - the answer involves a specific gene, and proposes changes to the future of treatment.
Muy-Teck Teh, Senior Lecturer from Barts and the London School of Medicine & Dentistry, Queen Mary University of London discusses how a novel low-cost rapid digital diagnostic test could help save lives and reduce head and neck cancer burden worldwide.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group, China charts how to deal with dementia during the COVID-19 pandemic, starting with a helpful global and regional overview.
Shinichi Tokuno from the University of Tokyo walks us through voice analysis technology, specifically focussing on social impact analysis using voice biomarkers.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group, provides a cancer focus, in particular, she details breakthrough technologies that allow leveraging biomarkers for oncology.
Heinz Zwierzina M.D., CDDF Managing Director tells us all about biomarkers and patients’ access to personalised oncology drugs in Europe in this insightful article
Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH shares his views on data-based solutions for diabetes.
Managing Director of The Cancer Drug Development Forum, Prof. H. Zwierzina reveals his opinions on the current and future challenges of personalised cancer therapy, including the need for biomarkers.
Advertisements
Latest Academic Articles
The latest academic articles from key research stakeholders
